204 related articles for article (PubMed ID: 9783598)
1. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
Hausheer FH; Shanmugarajah D; Leverett BD; Chen X; Huang Q; Kochat H; Petluru PN; Parker AR
Cancer Chemother Pharmacol; 2010 Apr; 65(5):941-51. PubMed ID: 19714332
[TBL] [Abstract][Full Text] [Related]
3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
4. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
5. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
6. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
7. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
8. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
10. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
13. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
14. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
15. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Verschraagen M; Kedde MA; Hausheer FH; Van Der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):499-504. PubMed ID: 12715205
[TBL] [Abstract][Full Text] [Related]
16. Mesna inactivates platinum agents in vitro.
Wolff JE; Egeler RM; Anderson R; Ujack E; Iceton S; Coppes MJ
Anticancer Res; 1998; 18(6A):4077-81. PubMed ID: 9891448
[TBL] [Abstract][Full Text] [Related]
17. Evolution of chemotherapy with platinum compounds.
Walker EM; Walker SM
Ann Clin Lab Sci; 1999; 29(4):263-74. PubMed ID: 10528825
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of cytotoxics-platinum agents.
Selvaratnam G; Philips RH; Mohamed AK; Radzi A
Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
[No Abstract] [Full Text] [Related]
20. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
Parker AR; Petluru PN; Wu M; Zhao M; Kochat H; Hausheer FH
Mol Cancer Ther; 2010 Sep; 9(9):2558-67. PubMed ID: 20807779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]